Icahn School of Medicine at Mount Sinai


 

Developing KCNQ Channel Openers as Novel Antidepressants: Rationale for Targeting the KCNQ2/3 Channels for Depression & Anhedonia

8 views
May 18, 2021
Comments 0
Login to view comments. Click here to Login